OTC Products
FDA approves a second OTC naloxone nasal spray
July 31, 2023Medical Communications FDA, Nasal Spray, OTC, OTC Products, naloxone, opioids
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg naloxone hydrochloride nasal spray for …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
